Do Not Do Recommendation

 
Dapagliflozin in a triple therapy regimen in combination with metformin and a sulfonylurea is not recommended for treating type 2 diabetes, except as part of a clinical trial.

Do Not Do Recommendation Details

Recommendation:
Dapagliflozin in a triple therapy regimen in combination with metformin and a sulfonylurea is not recommended for treating type 2 diabetes, except as part of a clinical trial.
Interventions:
Dapagliflozin in a triple therapy regimen in combination with metformin and a sulfonylurea

Source guidance details

Guidance:
Type 2 diabetes - Dapagliflozin combination therapy: guidance (TA288)
Published date:
June 2013
Paragraph number:
1.3
Page number:
3

View all NICE do not do from this Guidance

There are no other recommendations for this guidance.